<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03769103</url>
  </required_header>
  <id_info>
    <org_study_id>LUOSICNS</org_study_id>
    <nct_id>NCT03769103</nct_id>
  </id_info>
  <brief_title>Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC</brief_title>
  <official_title>Open Label, Multicenter, Phase II Study of Patients With Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, multicenter, randomized phase II study will evaluate the usage of
      osimertinib alone for brain metastases compared to SRS and osimertinib in patients with newly
      diagnosed, treatment naiive EGFR positive lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2019</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Absence of progressive brain metastases according to the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intracranial overall response rate</measure>
    <time_frame>2 years</time_frame>
    <description>partial or complete response to therapy based on RANO-BM criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to whole brain radiotherapy (WBRT)</measure>
    <time_frame>2 years</time_frame>
    <description>time from randomization to WBRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to stereotactic radiosurgery (SRS)</measure>
    <time_frame>2 years</time_frame>
    <description>time from randomization to SRS (not including initial SRS in the SRS + osimertinib treatment arm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of radionecrosis</measure>
    <time_frame>2 years</time_frame>
    <description>according to institutional standards based on radiologic findings with or without pathologic confirmation and multidisciplinary review when required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>defined as time from randomization to death by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant progression</measure>
    <time_frame>2 years</time_frame>
    <description>time from randomization to progression of extracranial metastases or development of new sites of disease per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30. Subscales for: general presence of symptoms in patients with cancer question 1-28 (1=Not at all; 4=very much); overall health/quality of life question 29-30 (1=very poor; 7=excellent) &amp; EORTC-QLQ Brain Neoplasm (BN)20: Subscales for presence of symptoms in patients with brain tumours question 31-50 (1=Not at all; 4=very much)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by Montreal Cognitive Assessment. Total score:30. 1=poor function; 30=good function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure to osimertinib</measure>
    <time_frame>2 years</time_frame>
    <description>Osimertinib dose (40mg or 80mg) for x number of days (max=730 days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Lung Cancer Non-small Cell Stage IV</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>SRS + Osimertinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stereotactic radiotherapy will be delivered in 1-5 fractions to each brain metastases according to the volume and location of the metastases and clinician discretion. Osimertinib will start 1-7 days post radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osimertinib alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Osimertinib 80mg PO daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Daily oral osimertinib</description>
    <arm_group_label>Osimertinib alone</arm_group_label>
    <arm_group_label>SRS + Osimertinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy</intervention_name>
    <description>1-5 fractions of stereotactic radiotherapy</description>
    <arm_group_label>SRS + Osimertinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written informed consent by patient or legally acceptable
             representative

          -  Meets the criteria in the approved regulatory indication for first line treatment with
             osimertinib and agree to the restrictions, monitoring, and dose-adjustment criteria
             stipulated in the associated product label

          -  Epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R)
             substitution mutations (either alone or in combination with other EGFR mutations)

          -  No prior systemic therapy except neoadjuvant, adjuvant or concurrent chemotherapy
             given greater than 3 months prior to enrollment on study

          -  Asymptomatic or minimally symptomatic brain metastases (ie. Headache, nausea, or
             seizure responsive to dexamethasone/analgesic/antiepileptic on stable doses of
             medications for a minimum of 3 days)

          -  Brain metastases must meet the following criteria on a diagnostic MRI: at least one
             lesion can be classified as measurable disease per RANO-BM, ≤ 10 brain or brainstem
             metastases, ≤ 30 mm and brainstem metastases must be ≤ 5 mm, metastases &gt; 5 mm from
             the optic nerve or chiasm

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 6 months

          -  Willing to abstain from sexual activity or willing to use double-barrier method during
             sexual intercourse

        Exclusion Criteria:

          -  Previous treatment with osimertinib, or any other EGFR TKI

          -  Patient with symptomatic brain metastases causing any neurologic deficit (not
             including headache, nausea, or medically controlled seizure)

          -  Multiple sclerosis

          -  Pacemaker or MRI-incompatible metal in the body

          -  Allergy to gadolinium MRI contrast

          -  Brain metastasis requiring surgery for decompression

          -  Leptomeningeal disease

          -  Previous cranial RT, or surgery for brain metastases

          -  Uncontrolled systemic lupus erythematosis, scleroderma or other connective tissue
             disorders considered a contraindication for radiotherapy

          -  Active cancer from another anatomical site within 5 years (non-melanomatous skin and
             cervical cancers permitted)

          -  Any medical or non-medical issue that would render patient unable to reliably complete
             regular QOL and neurocognitive assessments

          -  Judgment by the investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions and requirements

          -  Treatment with an investigational drug within five half-lives of the compound or 3
             months, whichever is greater

          -  Patients with symptomatic CNS metastases who are neurologically unstable

          -  Patients currently receiving (or unable to stop use prior to receiving the first dose
             of study treatment) medications or herbal supplements known to be potent inducers of
             cytochrome P450 (CYP) 3A4

          -  Patients taking any drugs that are known to prolong QT interval that can't be
             withdrawn prior to Osimertinib

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shilo V Lefresne, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>BC Cancer, Vancouver Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheryl Ho, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>BC Cancer, Vancouver Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shilo V Lefresne, MD, FRCPC</last_name>
    <phone>604 877 6000</phone>
    <phone_ext>2673</phone_ext>
    <email>SLefresne@bccancer.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheryl Ho, MD, FRCPC</last_name>
    <phone>604 877 6000</phone>
    <email>cho@bccancer.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BC Cancer, Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shilo Lefresne, MD</last_name>
      <phone>604 877 6000</phone>
      <phone_ext>2673</phone_ext>
      <email>slefresne@bccancer.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Cheryl Ho, MD</last_name>
      <phone>604 877 6000</phone>
      <phone_ext>2445</phone_ext>
      <email>cho@bccancer.bc.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Sacher</last_name>
    </contact>
    <contact_backup>
      <last_name>David Shultz</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Doherty</last_name>
    </contact>
    <contact_backup>
      <last_name>Arjun Sahgal</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR positive</keyword>
  <keyword>Osimertinib</keyword>
  <keyword>SRS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

